<prompt> Which of the following antiplatelet drugs is a P2Y12 receptor blocker not effected by CYP2C19 polymorphism:ClopidogrelPrasugrelEpitifibatideDipyridamole  <response>: Prasuagrel is a third-generation thienopyridine antiplatelet agent that binds irreversibly to the P2RY12 receptor and inhibits ADP-mediated platelet activation and aggregation. The pharmacokinetics of prasuagrel;s active metabolite is not known to be effective by genetic variations in CYP2C19 genotype. P2Y12 receptor Blockers P2Y12 Receptor Blockers are a group of Anti-platelet agents that inhibit the binding of ADP to its receptors on platelets and inhibit platelet aggregation. Inhibit the activation of the GP IIbIIIa receptors required for platelets to bind to fibrinogen and to each other. P2Y12 receptor belongs a group of G-protein-coupled GPCR purinergic receptors that are chemoreceptor for adenosine diphosphate ADP Irreversible Thienopyridines Reversible Cyclopentyltriaolo-pyrimidines Ticlopidine oral First generation Clopidogrel Oral Second generation Prasugrel Oral Third Generation Ticagrelor Oral Cangrelor Intravenous Ref: Goodman and Gilman 13th edition Pgno: 597 